Gilead Sciences Announces Completion of Acquisition of CymaBay

Gilead Sciences, Inc. (Nasdaq: GILD) has announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients.

Read the full article: Gilead Sciences Announces Completion of Acquisition of CymaBay //

Source: https://www.businesswire.com/news/home/20240322979704/en/Gilead-Sciences-Announces-Completion-of-Acquisition-of-CymaBay

Leave a Comment

Your email address will not be published.

Scroll to Top